10.1021/bc500016k.s001
Karen
C. Collins
Karen
C.
Collins
Kim D. Janda
Kim D.
Janda
Investigating Hapten Clustering as a Strategy to Enhance
Vaccines against Drugs of Abuse
American Chemical Society
2015
antibody affinity
concentration
vaccine paradigm
Hapten Clustering
Enhance Vaccines
trivalent hapten
diglycine spacer
abuse
monovalent AM 1 analog
equivalent affinity
response
hapten density
context
2015-12-17 01:05:10
Journal contribution
https://acs.figshare.com/articles/journal_contribution/Investigating_Hapten_Clustering_as_a_Strategy_to_Enhance_Vaccines_against_Drugs_of_Abuse/2030139
Vaccines for drugs of abuse have
yet to achieve full clinical relevance,
largely due to poor/inconsistent immune responses in patients. The
use of multivalent scaffolding as a means to tailor drug–hapten
density and clustering was examined in the context of drug-immune
response modulation. A modular trivalent hapten containing a diglycine
spacer, triAM1(Gly)<sub>2</sub>, was synthesized and shown to elicit
anti-nicotine antibodies at equivalent affinity and concentration
to the monovalent AM1 analog, despite in this instance having a lower
effective hapten density. Augmenting this data, the corresponding
monovalent hapten AM1(Gly)<sub>2</sub> resulted in enhanced antibody
affinity and concentration. Drug-hapten clustering represents a new
vaccine paradigm, and, while examined only in the context of nicotine,
it should be readily translatable to other drugs of abuse.